



PATENT
Customer No. 22,852
Attorney Docket No. 3495.0010-24

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Marc ALIZON et al.) Group Art Unit: 1637
Application No.: 08/475,822) Examiner: Jeffery N. FREDMAN
Filed: June 7, 2005) Confirmation No.: 4832
)

For: CLONED DNA SEQUENCES RELATED TO THE GENOMIC RNA OF
LYMPHADENOPATHY-ASSOCIATED VIRUS (LAV) AND PROTEINS
ENCODED BY SAID LAV GENOMIC RNA

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), applicants bring to the attention of the Examiner the documents on the attached listing. This Information Disclosure Statement is being filed before the mailing date of a first Office Action after the filing of a Request for Examination After Final under 37 C.F.R. § 1.129(a) in the above-referenced application.

Copies of the listed documents are enclosed.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed

documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and applicants determine that the cited documents do not constitute "prior art" under United States law, applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should the documents be applied against the claims of the present application.


If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: March 9, 2005

By:



Salvatore J. Arrigo
Reg. No. 46,063
Telephone: 202-408-4160
Facsimile: 202-408-4400
E-mail: arrigos@finnegan.com

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)


Sheet

1

of

Complete if Known

<i>Application Number</i>	08/475,822
<i>Filing Date</i>	June 7, 1995
<i>First Named Inventor</i>	Marc ALIZON et al.
<i>Art Unit</i>	1637
<i>Examiner Name</i>	Jeffrey N. FREDMAN
<i>Attorney Docket Number</i>	3495.0010-24



U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS

Note: Copies of the U.S. Patent Documents are not Required in IDS filed after October 21, 2004

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation ⁶

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation ⁶
		Paper No. 300 in Interference No. 102,822; APJs Metz, Pate, and Martin; 03/09/2001; pp. 1-6.	
		Paper No. 271 in Interference No. 102,822; APJs Metz, Pate, and Martin; 04/21/1999; pp. 1-3.	
		Paper No. 282 in Interference No. 102,822; APJs Metz, Pate, and Martin; 07/30/1999; pp. 1-2.	
		Paper No. 289 in Interference No. 102,822; APJs Metz, Pate, and Martin; 10/19/1999; pp. 1-3.	
		Copies of claims 30, 31, 57-61, 109-115, and 132 in Interference No. 102,822.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.